Vera Therapeutics faces a pivotal moment with Phase 3 data expected soon. Depending on the result, the stock may spike or ...

Detailed price information for Vera Therapeutics Inc Cl A (VERA-Q) from The Globe and Mail including charting and trades.

Inc. (Nasdaq: VERA) today announced that on May 5, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 111,750 shares of Class A common ...

World No 3 Alexander Zverev blamed illness after a last 16 elimination by Frenchman Alexandre Muller in the Hamburg Open on ...

The Subject Expert Committee (SEC) on Haematology, functional under the Central Drugs Standard Control Organisation (CDSCO) ...

Aurinia is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) for the potential treatment of autoimmune diseases.

IgA Nephropathy (IgAN), Primary Membranous Nephropathy (pMN) and Other B Cell-Mediated Diseases Vertex is developing povetacicept, a dual antagonist of the BAFF and APRIL cytokines, which play key ...

The United States and China agreed Monday to slash their massive recent tariffs, restarting stalled trade between the world's ...

Aurinia Pharmaceuticals Inc (AUPH) reports a 24% revenue increase and significant cash flow improvements, while navigating patent challenges and advancing its drug pipeline.

Aurinia is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Canada Post is ...

Aurinia is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Canadian ...